Table 2 Association between SEC14L1 protein expression and the clinicopathological factors
Factors | Expression of SEC14L1 | ||||
---|---|---|---|---|---|
Low | High | Total | p-Value | ||
Tumor size | ≥ 2 cm | 68 (68.7%) | 31 (31.3%) | 99 | 0.75 |
< 2 cm | 49 (71.0%) | 20 (29.0%) | 69 | ||
Nodal status | Positive | 55 (67.1%) | 27 (32.9%) | 82 | 0.48 |
Negative | 62 (72.1%) | 24 (27.9%) | 86 | ||
Histological grade | Grade 3 | 53 (60.9%) | 34 (39.1%) | 87 | 0.011 |
Grade 1, 2 | 64 (79.0%) | 17 (21.0%) | 81 | ||
Lymphovascular invasion | Positive | 43 (51.8%) | 40 (48.2%) | 83 | < 0.0001 |
Negative | 74 (88.1%) | 10 (11.9%) | 84 | ||
Estrogen receptor | Positive | 85 (69.1%) | 38 (30.9%) | 123 | 0.80 |
Negative | 32 (71.1%) | 13 (28.9%) | 45 | ||
Progesterone receptor | Positive | 66 (70.2%) | 28 (29.8%) | 94 | 0.96 |
Negative | 44 (69.8%) | 19 (30.2%) | 63 | ||
HER2 | Positive | 14 (53.8%) | 12 (46.2%) | 26 | 0.036 |
Negative | 98 (74.2%) | 34 (25.8%) | 132 | ||
Molecular subtypes | Luminal A-like | 30 (88.2%) | 4 (11.8%) | 34 | 0.006 |
Luminal B-like | 39 (65.0%) | 21 (35.0%) | 60 | ||
HER2-positive | 14 (53.8%) | 12 (46.2%) | 26 | ||
Triple negative | 23 (85.2%) | 4 (14.8%) | 27 |